
By the end of this year, the biotech expects to have 270 employees in Baltimore’s Camden-Carroll neighborhood.

By the end of this year, the biotech expects to have 270 employees in Baltimore’s Camden-Carroll neighborhood.

Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine Vivotif® (Typhoid Vaccine Live Oral Ty21a) in five additional European Union Member States, including France, Portugal, Poland, Czech Republic and Slovakia as well as approval of harmonized prescribing information in the EU also known as the Summary of Product Characteristics or SmPC.

BioHealth Innovation has announced the schedule for the next year’s Entrepreneur-in Residence (EIR) feedback sessions. These 1:1 Sessions with EIRs take place at BioHealth Innovation’s office in Rockville OR by videoconference. There is no charge to participate but entrepreneurs must be working on a biohealth Start-Ups/innovation in the BioHealth Capital Region (MD, DC, VA). The upcoming dates are:
2019: 5/22, 7/24, 9/4, 10/9, 11/20
2020: 1/22, 2/26, 3/25, 4/22, 5/27
Schedule your appointment online here. For questions or more information, contact BHI.

The company will use the funding to grow two business lines.

The Maryland Stem Cell Research Commission (Commission) has approved funding to its second round of 2019 recipients for a total of $6,622,673.63. The Commission has also issued its Request for Applications (RFAs) for its first round of funding for fiscal year 2020.

NextStep Robotics Inc., an early-stage company that has developed a personalized robotic therapy to help treat foot drop in recovering stroke patients, announces the closing of its second funding round. The $600,000 round will allow NextStep to transition from prototyping and development to manufacturing and sales. Led by the Abell Foundation, a new investor, this round includes investments from previous private investors from Vancouver, Canada and new investors the Abell Foundation, University of Maryland (UM) Ventures, and Jeff and Brad Quinn of Engineered Medical Systems, Inc. (EMS), a partner company of the newly-formed LaunchPort™ Accelerator.

AS A CHILD, Susan Hockfield took apart anything she got her hands on to figure out how it worked. One time it was a watch, another time her mother’s iron. Her interest in the anatomy of the physical world grew over time: She pursued a career in neurobiology, and went on to teach at Yale University, where she eventually became provost. In 2005 she became the first female president of the Massachusetts Institute of Technology — and its first biologist-president.

The U.S. government invests a significant amount of money to further research and technology innovation. In 2017, the federal government invested approximately $150 billion in R&D— about one-third at the 17 federal laboratories across the country and two-thirds at universities and private sector R&D institutions, according to government reports. This represents about one-third of all U.S. R&D spending.

The submission to Arlington County ends months of speculation.

The Biomedical Advanced Research and Development Authority (BARDA) will begin procuring Emergent BioSolutions’ anthrax vaccine into the Strategic National Stockpile (SNS) to strengthen U.S. preparedness in the event of a public health threat, the company said on Wednesday.